WO2006071773A3 - Treatment of osteochondral diseases using postpartum-derived cells and products thereof - Google Patents

Treatment of osteochondral diseases using postpartum-derived cells and products thereof Download PDF

Info

Publication number
WO2006071773A3
WO2006071773A3 PCT/US2005/046782 US2005046782W WO2006071773A3 WO 2006071773 A3 WO2006071773 A3 WO 2006071773A3 US 2005046782 W US2005046782 W US 2005046782W WO 2006071773 A3 WO2006071773 A3 WO 2006071773A3
Authority
WO
WIPO (PCT)
Prior art keywords
postpartum
products
treatment
derived cells
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/046782
Other languages
French (fr)
Other versions
WO2006071773A2 (en
Inventor
Laura Brown
Sridevi Dhanaraj
Agnieszka Seyda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc filed Critical Ethicon Inc
Priority to EP05855357A priority Critical patent/EP1838842A2/en
Publication of WO2006071773A2 publication Critical patent/WO2006071773A2/en
Publication of WO2006071773A3 publication Critical patent/WO2006071773A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/19—Growth and differentiation factors [GDF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products such as lysates related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions such as osteoarthritis.
PCT/US2005/046782 2004-12-23 2005-12-22 Treatment of osteochondral diseases using postpartum-derived cells and products thereof Ceased WO2006071773A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05855357A EP1838842A2 (en) 2004-12-23 2005-12-22 Treatment of osteochondral diseases using postpartum-derived cells and products thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63870304P 2004-12-23 2004-12-23
US60/638,703 2004-12-23

Publications (2)

Publication Number Publication Date
WO2006071773A2 WO2006071773A2 (en) 2006-07-06
WO2006071773A3 true WO2006071773A3 (en) 2006-12-21

Family

ID=36615443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046782 Ceased WO2006071773A2 (en) 2004-12-23 2005-12-22 Treatment of osteochondral diseases using postpartum-derived cells and products thereof

Country Status (2)

Country Link
EP (1) EP1838842A2 (en)
WO (1) WO2006071773A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916146B2 (en) 2007-02-12 2014-12-23 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9234172B2 (en) 2003-06-27 2016-01-12 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US9498501B2 (en) 2003-06-27 2016-11-22 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
WO2006071778A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
WO2007070870A1 (en) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
ZA200902233B (en) * 2006-10-23 2010-07-28 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
AU2008216748A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
EP2164953A4 (en) 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD FOR ISOLATING PLACENTA FROM STEM AND PROGENITOR CELLS
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
CN102387807A (en) 2008-12-19 2012-03-21 先进科技及再生医学有限责任公司 Treatment of Lung Diseases and Conditions
US8771677B2 (en) 2008-12-29 2014-07-08 Vladimir B Serikov Colony-forming unit cell of human chorion and method to obtain and use thereof
SG174551A1 (en) 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
WO2011153512A2 (en) * 2010-06-03 2011-12-08 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
WO2012058617A1 (en) * 2010-10-29 2012-05-03 The Trustees Of Columbia University In The City Of New York Compositions and methods for formation of bone tissue
US8574899B2 (en) 2010-12-22 2013-11-05 Vladimir B Serikov Methods for augmentation collection of placental hematopoietic stem cells and uses thereof
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
AU2012358810B2 (en) 2011-12-23 2018-03-15 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
EP4008775A1 (en) 2015-03-04 2022-06-08 Mesoblast International Sàrl Cell culture method for mesenchymal stem cells
EP3327439A1 (en) * 2016-11-24 2018-05-30 Vito NV Flatbed exposure module for testing toxicity of nanoparticles on cells grown at air-liquid interface
KR20220054870A (en) * 2019-09-03 2022-05-03 엔리벡스 테라퓨틱스 리미티드 Therapeutic apoptotic cells to treat osteoarthritis
CN120204363A (en) * 2025-02-12 2025-06-27 中国人民解放军军事科学院军事医学研究院 Application of substances regulating protein FGF7 and drugs for treating or/and alleviating osteoarthritis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919702A (en) * 1996-10-23 1999-07-06 Advanced Tissue Science, Inc. Production of cartilage tissue using cells isolated from Wharton's jelly
US20030032179A1 (en) * 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2003068937A2 (en) * 2002-02-13 2003-08-21 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US20030161818A1 (en) * 2002-02-25 2003-08-28 Kansas State University Research Foundation Cultures, products and methods using stem cells
WO2003087392A2 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2004072273A1 (en) * 2003-02-11 2004-08-26 Davies John E Progenitor cells from wharton's jelly of human umbilical cord
WO2005001076A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum cells derived from placental tissue, and methods of making and using the same

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919702A (en) * 1996-10-23 1999-07-06 Advanced Tissue Science, Inc. Production of cartilage tissue using cells isolated from Wharton's jelly
US20030032179A1 (en) * 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2003068937A2 (en) * 2002-02-13 2003-08-21 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US20030161818A1 (en) * 2002-02-25 2003-08-28 Kansas State University Research Foundation Cultures, products and methods using stem cells
WO2003087392A2 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2004072273A1 (en) * 2003-02-11 2004-08-26 Davies John E Progenitor cells from wharton's jelly of human umbilical cord
WO2005001076A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum cells derived from placental tissue, and methods of making and using the same
WO2005003334A2 (en) * 2003-06-27 2005-01-13 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
WO2005038012A2 (en) * 2003-06-27 2005-04-28 Ethicon Incorporated Cartilage and bone repair and regeneration using postpartum-derived cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
EBLENKAMP M ET AL: "[Umbilical cord stromal cells (UCSC). Cells featuring osteogenic differentiation potential]", DER ORTHOPADE. DEC 2004, vol. 33, no. 12, December 2004 (2004-12-01), pages 1338 - 1345, XP002331941, ISSN: 0085-4530 *
FUKUCHI Y ET AL: "HUMAN PLACENTA-DERIVED CELLS HAVE MESENCHYMAL STEM/PROGENITOR CELL POTENTIAL", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 22, no. 5, 2004, pages 649 - 658, XP009046573, ISSN: 1066-5099 *
ISHII M ET AL: "Molecular markers distinguish bone marrow mesenchymal stem cells from fibroblasts", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 332, no. 1, 24 June 2005 (2005-06-24), pages 297 - 303, XP004892979, ISSN: 0006-291X *
JOHNSTONE B ET AL: "IN VITRO CHONDROGENESIS OF BONE MARROW-DERIVED MESENCHYMAL PROGENITOR CELLS", EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 238, no. 1, 1998, pages 265 - 272, XP000881888, ISSN: 0014-4827 *
LODIE T A ET AL: "Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction", TISSUE ENGINEERING, LARCHMONT, NY, US, vol. 8, no. 5, October 2002 (2002-10-01), pages 739 - 751, XP002306489, ISSN: 1076-3279 *
MITCHELL K E ET AL: "Matrix cells from Wharton's jelly form neurons and glia", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 21, no. 1, January 2003 (2003-01-01), pages 50 - 60, XP002281007, ISSN: 1066-5099 *
ROMANOV YURI A ET AL: "Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord.", STEM CELLS (MIAMISBURG), vol. 21, no. 1, January 2003 (2003-01-01), pages 105 - 110, XP002331940, ISSN: 1066-5099 *
TREMAIN N ET AL: "MICROSAGE ANALYSIS OF 2,353 EXPRESSED GENES IN A SINGLE CELL-DERIVED COLONY OF UNDIFFERENTIATED HUMAN MESENCHYMAL STEM CELLS REVEALS MRNAS OF MULTIPLE CELL LINEAGES", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 19, 2001, pages 408 - 418, XP002907879, ISSN: 1066-5099 *
WULF G G ET AL: "MESENGENIC PROGENITOR CELLS DERIVED FROM HUMAN PLACENTA", TISSUE ENGINEERING, LARCHMONT, NY, US, vol. 10, no. 7/8, July 2004 (2004-07-01), pages 1136 - 1147, XP001206075, ISSN: 1076-3279 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234172B2 (en) 2003-06-27 2016-01-12 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US9498501B2 (en) 2003-06-27 2016-11-22 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9585918B2 (en) 2005-12-28 2017-03-07 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US8916146B2 (en) 2007-02-12 2014-12-23 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells

Also Published As

Publication number Publication date
EP1838842A2 (en) 2007-10-03
WO2006071773A2 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2006071773A3 (en) Treatment of osteochondral diseases using postpartum-derived cells and products thereof
WO2005038012A3 (en) Cartilage and bone repair and regeneration using postpartum-derived cells
WO2007016112A3 (en) Use of adipose tissue-derived stromal cells in spinal fusion
WO2006083394A3 (en) Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
ATE365045T1 (en) PRODUCTION OF SOFT AND BONE TISSUE USING PRECURSOR CELLS FROM MUSCLE, AS WELL AS ASSOCIATED COMPOSITIONS AND FORMS OF TREATMENT
IL147271A0 (en) Compounds that bind her2
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
UA95715C2 (en) Phosphadiazine derivatives, pharmaceutical composition and use thereof
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003221745A1 (en) rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EG25613A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2001094541A3 (en) Human mesenchymal progenitor cell
AU2003220115A1 (en) Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2006071777A3 (en) Soft tissue repair and regeneration using postpartum-derived cells and cell products
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
MY134738A (en) New product
WO2003029432A3 (en) Human mesenchymal progenitor cell
MX2007001876A (en) Vla-4 antagonists.
WO2004113305A3 (en) Diamino substituted quinazoline derivatives as promoters of smn2

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005855357

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application